Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction – a subgroup analysis of the LeoPARDS randomised trial

David B Antcliffe, Shalini Santhakumaranb, Robert M L Orme, Josie Ward, Farah Al-Beidh, Kieran O’Dea, Gavin D. Perkins, Mervyn Singer, Alexina J. Mason, Mary Cross, Danny McAuley, Deborah Ashby, Anthony Gordon

Research output: Contribution to specialist publicationArticle

30 Citations (Scopus)
115 Downloads (Pure)

Abstract

Purpose: Myocardial dysfunction is common in sepsis but optimal treatment strategies are unclear. The inodilator, levosimendan was suggested as a possible therapy, however, the Levosimendan to Prevent Acute Organ Dysfunction in Sepsis (LeoPARDS) trial found it to have no benefit in reducing organ dysfunction in septic shock. In this study we evaluated the effects of levosimendan in patients with and without biochemical cardiac dysfunction, and examined its non-inotropic effects.

Methods: Two cardiac biomarkers, troponin I (cTnI) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and five inflammatory mediators were measured in plasma from patients recruited to the LeoPARDS trial at baseline and over the first 6 days. Mean total Sequential Organ Failure Assessment (SOFA) score and 28-day mortality were compared between patients with normal and raised cTnI and NT-proBNP values, and between patients above and below median values.

Results: Levosimendan produced no benefit in SOFA score or 28-day mortality in patients with cardiac dysfunction. There was a statistically significant treatment by subgroup interaction (p=0.04) in patients with NT-proBNP above or below the median value. Those with NT-proBNP values above the median receiving levosimendan had higher SOFA scores than those receiving placebo (mean daily total SOFA score 7.64 (4.41) vs 6.09 (3.88), mean difference 1.55, 95%CI 0.43-2.68). Levosimendan had no effect on the rate of decline of inflammatory biomarkers.

Conclusion: Adding levosimendan to standard care in septic shock was not associated with less severe organ dysfunction nor lower mortality in patients with biochemical evidence of cardiac dysfunction.
Original languageEnglish
Pages1392–1400
Volume45
Specialist publicationIntensive Care Medicine
DOIs
Publication statusEarly online date - 19 Aug 2019

Fingerprint

Dive into the research topics of 'Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction – a subgroup analysis of the LeoPARDS randomised trial'. Together they form a unique fingerprint.

Cite this